News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Imprimis (immy) Patent-Pending Dropless And LessDrops Formulations Exceed One Million Patient Eyes Milestone



7/27/2017 6:46:59 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SAN DIEGO, July 27, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced its core patent-pending ophthalmic formulations have now served more than one million patient eyes.  Imprimis first began offering ophthalmic solutions to physicians three years ago with the launch of its GoDropless® campaign for cataract surgery.  By eliminating or reducing the need for post-surgery eye drop regimens, Dropless® injectable formulations, which have now been dispensed more than 500,000 times, have potentially saved Medicare, state governments and patients over 100 million dollars.  Additionally, Imprimis' affordably priced LessDrops® combination topical drops serve patients following cataract, refractive and other ocular procedures.  Dropless® and LessDrops® formulations, made in Imprimis' 503B FDA-registered and inspected outsourcing facility, adhere to Current Good Manufacturing Practices (cGMP), and are available for purchase by physicians, hospitals and surgery centers without the need for a patient-specific prescription. 

Imprimis has invested millions of dollars into quality systems and processes to protect the patient, including its innovative new packaging solutions.  LessDrops® formulations will now be shipped in a new color-coded label and bottle system designed to ensure proper performance, delivering approximately 90 drops from each bottle.  LessDrops® formulations, new bottle, and labeling system are available from the company's 503B FDA-registered outsourcing facility that participates in the FDA's MedWatch adverse event reporting system. 

LessDrops

Mark L. Baum, CEO of Imprimis, stated, "We are honored to have gained the trust of thousands of eye care professionals and their patients since we started these programs just over three years ago.  Imprimis is committed to providing high quality, innovative formulations at affordable prices, and adhering to this principle has undoubtedly helped us reach this important milestone.  Our innovative solutions, which all have come from the clinical experience of our physician-customers, have eliminated or reduced post-surgery drop regimens, provided better medication adherence and recovery, in addition to saving customers money compared to the standard of care." 

Baum continued, "It is gratifying to hear the peace of mind our customers have when we describe the investments we've made to ensure the quality of our products.  From equipment to training to providing educational tools on what to look out for when choosing a trusted pharmaceutical partner, physicians and their support staff are excited about how well our solutions function, how affordably they are priced and the excellent customer service we offer.  By collapsing the value chain for our customers, eliminating having to deal with insurance companies, benefit managers, and pharmacies that switch their prescriptions, Imprimis is putting power back in the prescriber's prescription pad."

About Dropless® Ophthalmic Surgery Formulations

Imprimis' proprietary ophthalmic formulations use patent-pending technologies to uniquely allow for the combination of drugs such as triamcinolone and moxifloxacin that do not typically distribute evenly in a suspension. Two compounded antibiotic and steroid formulations currently available in single, injectable, intraocular doses administered during ocular surgery include preservative-free combinations of triamcinolone acetonide and moxifloxacin hydrochloride and triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin. The relative strengths of the active ingredients can be tailored to individual patients. Intraoperative administration of drugs has been shown to reduce both non-compliance and patient error, significantly lessening the surgeon's concern and elevating the patient's experience with cataract surgery. 1-2 Physicians have prescribed Imprimis' proprietary formulations for use in thousands of cataract surgeries, and have reported advantages including reduction of compliance concerns and reduction of staff and chair time spent on instructions and follow-up with post-operative surgical patients and pharmacists.1-2 For more information, please visit www.DropLess.com

About Imprimis' LessDrops®Combination Drops

Imprimis' portfolio of combination drop therapy topical formulations may require up to 50% fewer drops to be administered by patients and may provide significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments. The LessDrops® educational campaign aims to improve patient compliance and alleviate patient confusion associated with complex eye drop regimens. For more information, please visit www.LessDrops.com.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states. The company's unique business model increases patient access and affordability to many critical medicines.  Headquartered in San Diego, California, Imprimis owns and operates production and dispensing facilities located in California and New Jersey. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com

Safe Harbor

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; our ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Other than drugs compounded at a registered outsourcing facility, all Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws.

1 Liegner J. Better surgery through chemicals. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

2 Galloway MS. Intravitreal placement of antibiotic/steroid as a substitute for post-operative drops following cataract surgery. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

Imprimis Pharmaceuticals Contacts

Media Contact
Deb Holliday
deb@pascalecommunications.com
412.877.4519

Investor Contact
Jon Patton
jpatton@imprimispharma.com
858.704.4587                                                                                                    

 

Imprimis Pharmaceuticals Logo (PRNewsFoto/Imprimis Pharmaceuticals)

View original content with multimedia:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-patent-pending-dropless-and-lessdrops-formulations-exceed-one-million-patient-eyes-milestone-300495036.html

SOURCE Imprimis Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES